Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer.
Int Braz J Urol
; 49(4): 479-489, 2023.
Article
en En
| MEDLINE
| ID: mdl-37267613
ABSTRACT
PURPOSE:
To evaluate the potential oncologic benefit of a visibly complete transurethral resection of a bladder tumor (TURBT) prior to neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). MATERIALS ANDMETHODS:
We identified patients who received NAC and RC between 2011-2021. Records were reviewed to assess TURBT completeness. The primary outcome was pathologic downstaging (RESULTS:
We identified 153 patients, including 116 (76%) with a complete TURBT. Sixty-four (42%) achievedCONCLUSIONS:
A visibly complete TURBT was not associated with pathologic downstaging, cancer-specific or recurrence-free survival following NAC and RC. These data do not support the need for repeat TURBT to achieve a visibly complete resection if NAC and RC are planned.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Vejiga Urinaria
/
Terapia Neoadyuvante
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article